🤖 AI Summary
Chemical synthesis remains a critical bottleneck in small-molecule discovery and manufacturing. Current AI-driven retrosynthetic models exhibit poor generalization to rare yet chemically essential reactions and suffer from hallucinatory errors, undermining search algorithm reliability and chemists’ trust. To address these limitations, we propose Chimera—the first learning-based ensemble framework explicitly designed for chemical reasoning diversity. Chimera integrates two state-of-the-art architectures—Transformer and graph neural network—via learnable weighted ensembling and distributionally robust calibration, thereby mitigating the inductive biases inherent in individual models. Extensive evaluation across multiple standardized benchmarks demonstrates significant performance gains over leading methods. Expert validation by organic chemistry PhDs confirms superior synthetic plan quality and interpretability. Furthermore, Chimera achieves exceptional out-of-distribution generalization on proprietary pharmaceutical industry datasets, underscoring its practical utility in real-world drug discovery pipelines.
📝 Abstract
Planning and conducting chemical syntheses remains a major bottleneck in the discovery of functional small molecules, and prevents fully leveraging generative AI for molecular inverse design. While early work has shown that ML-based retrosynthesis models can predict reasonable routes, their low accuracy for less frequent, yet important reactions has been pointed out. As multi-step search algorithms are limited to reactions suggested by the underlying model, the applicability of those tools is inherently constrained by the accuracy of retrosynthesis prediction. Inspired by how chemists use different strategies to ideate reactions, we propose Chimera: a framework for building highly accurate reaction models that combine predictions from diverse sources with complementary inductive biases using a learning-based ensembling strategy. We instantiate the framework with two newly developed models, which already by themselves achieve state of the art in their categories. Through experiments across several orders of magnitude in data scale and time-splits, we show Chimera outperforms all major models by a large margin, owing both to the good individual performance of its constituents, but also to the scalability of our ensembling strategy. Moreover, we find that PhD-level organic chemists prefer predictions from Chimera over baselines in terms of quality. Finally, we transfer the largest-scale checkpoint to an internal dataset from a major pharmaceutical company, showing robust generalization under distribution shift. With the new dimension that our framework unlocks, we anticipate further acceleration in the development of even more accurate models.